Medicines access programs to cancer medicines in Australia and New Zealand: An exploratory study

Piyush Grover, Zaheer-Ud-Din Babar, Raoul Oehmen, Agnes Vitry

Research output: Contribution to journalArticle

Abstract

Medicines Access Programs (MAP) offer access to publicly unfunded medicines at the discretion of pharmaceutical companies. Limited literature is available on their extent and scope in Australia and New Zealand. This study aims to identify MAPs for cancer medicines that were operational in 2014-15 in Australia and New Zealand and describe their characteristics. A preliminary list of MAPs was sent to hospital pharmacists in Australia and New Zealand to validate and collect further information. Pharmaceutical companies were contacted directly to provide information regarding MAPs offered. Key stakeholders were interviewed to identify issues with MAPs. Fifty-one MAPs were identified covering a range of indications. The majority of MAPs were provided free of charge to the patient for medicines that were registered or in the process of being registered but were not funded. Variability in the number of MAPs across institutions and characteristics was observed. Australia offered more MAPs than New Zealand. Only two of 17 pharmaceutical companies contacted agreed to provide information on their MAPs. Eight stakeholder interviews were conducted. This identified that while MAPs are widely operational there is lack of clinical monitoring, inequity to access, operational issues and lack of transparency. Our results suggest a need for a standardised and mandated policy to mitigate issues with MAPs.

LanguageEnglish
Pages243-249
Number of pages7
JournalHealth Policy
Volume122
Issue number3
Early online date20 Dec 2017
DOIs
Publication statusPublished - Mar 2018

Fingerprint

New Zealand
Neoplasms
Pharmaceutical Preparations
Pharmacists
Interviews

Cite this

Grover, Piyush ; Babar, Zaheer-Ud-Din ; Oehmen, Raoul ; Vitry, Agnes. / Medicines access programs to cancer medicines in Australia and New Zealand : An exploratory study. In: Health Policy. 2018 ; Vol. 122, No. 3. pp. 243-249.
@article{c59310f6ed3a4e34894ac2514b0e7f92,
title = "Medicines access programs to cancer medicines in Australia and New Zealand: An exploratory study",
abstract = "Medicines Access Programs (MAP) offer access to publicly unfunded medicines at the discretion of pharmaceutical companies. Limited literature is available on their extent and scope in Australia and New Zealand. This study aims to identify MAPs for cancer medicines that were operational in 2014-15 in Australia and New Zealand and describe their characteristics. A preliminary list of MAPs was sent to hospital pharmacists in Australia and New Zealand to validate and collect further information. Pharmaceutical companies were contacted directly to provide information regarding MAPs offered. Key stakeholders were interviewed to identify issues with MAPs. Fifty-one MAPs were identified covering a range of indications. The majority of MAPs were provided free of charge to the patient for medicines that were registered or in the process of being registered but were not funded. Variability in the number of MAPs across institutions and characteristics was observed. Australia offered more MAPs than New Zealand. Only two of 17 pharmaceutical companies contacted agreed to provide information on their MAPs. Eight stakeholder interviews were conducted. This identified that while MAPs are widely operational there is lack of clinical monitoring, inequity to access, operational issues and lack of transparency. Our results suggest a need for a standardised and mandated policy to mitigate issues with MAPs.",
keywords = "Cancer medicines, Compassionate use, Medicines access programs, Pharmaceutical policy",
author = "Piyush Grover and Zaheer-Ud-Din Babar and Raoul Oehmen and Agnes Vitry",
year = "2018",
month = "3",
doi = "10.1016/j.healthpol.2017.12.004",
language = "English",
volume = "122",
pages = "243--249",
journal = "Health Policy",
issn = "0168-8510",
publisher = "Elsevier",
number = "3",

}

Medicines access programs to cancer medicines in Australia and New Zealand : An exploratory study. / Grover, Piyush; Babar, Zaheer-Ud-Din; Oehmen, Raoul; Vitry, Agnes.

In: Health Policy, Vol. 122, No. 3, 03.2018, p. 243-249.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Medicines access programs to cancer medicines in Australia and New Zealand

T2 - Health Policy

AU - Grover, Piyush

AU - Babar, Zaheer-Ud-Din

AU - Oehmen, Raoul

AU - Vitry, Agnes

PY - 2018/3

Y1 - 2018/3

N2 - Medicines Access Programs (MAP) offer access to publicly unfunded medicines at the discretion of pharmaceutical companies. Limited literature is available on their extent and scope in Australia and New Zealand. This study aims to identify MAPs for cancer medicines that were operational in 2014-15 in Australia and New Zealand and describe their characteristics. A preliminary list of MAPs was sent to hospital pharmacists in Australia and New Zealand to validate and collect further information. Pharmaceutical companies were contacted directly to provide information regarding MAPs offered. Key stakeholders were interviewed to identify issues with MAPs. Fifty-one MAPs were identified covering a range of indications. The majority of MAPs were provided free of charge to the patient for medicines that were registered or in the process of being registered but were not funded. Variability in the number of MAPs across institutions and characteristics was observed. Australia offered more MAPs than New Zealand. Only two of 17 pharmaceutical companies contacted agreed to provide information on their MAPs. Eight stakeholder interviews were conducted. This identified that while MAPs are widely operational there is lack of clinical monitoring, inequity to access, operational issues and lack of transparency. Our results suggest a need for a standardised and mandated policy to mitigate issues with MAPs.

AB - Medicines Access Programs (MAP) offer access to publicly unfunded medicines at the discretion of pharmaceutical companies. Limited literature is available on their extent and scope in Australia and New Zealand. This study aims to identify MAPs for cancer medicines that were operational in 2014-15 in Australia and New Zealand and describe their characteristics. A preliminary list of MAPs was sent to hospital pharmacists in Australia and New Zealand to validate and collect further information. Pharmaceutical companies were contacted directly to provide information regarding MAPs offered. Key stakeholders were interviewed to identify issues with MAPs. Fifty-one MAPs were identified covering a range of indications. The majority of MAPs were provided free of charge to the patient for medicines that were registered or in the process of being registered but were not funded. Variability in the number of MAPs across institutions and characteristics was observed. Australia offered more MAPs than New Zealand. Only two of 17 pharmaceutical companies contacted agreed to provide information on their MAPs. Eight stakeholder interviews were conducted. This identified that while MAPs are widely operational there is lack of clinical monitoring, inequity to access, operational issues and lack of transparency. Our results suggest a need for a standardised and mandated policy to mitigate issues with MAPs.

KW - Cancer medicines

KW - Compassionate use

KW - Medicines access programs

KW - Pharmaceutical policy

UR - http://www.scopus.com/inward/record.url?scp=85039724620&partnerID=8YFLogxK

U2 - 10.1016/j.healthpol.2017.12.004

DO - 10.1016/j.healthpol.2017.12.004

M3 - Article

VL - 122

SP - 243

EP - 249

JO - Health Policy

JF - Health Policy

SN - 0168-8510

IS - 3

ER -